key: cord-0743474-u2qkzpjx
authors: Romon, Iñigo; Arroyo, Jose L.; Díaz, Teresa; Dominguez‐Garcia, Juan J; Briz, Montserrat
title: High‐titre anti‐SARS‐CoV‐2 convalescent plasma donation after donors’ vaccination
date: 2021-03-21
journal: Vox Sang
DOI: 10.1111/vox.13094
sha: 9476110f2fd058e882a5226157c0280778572c9f
doc_id: 743474
cord_uid: u2qkzpjx

nan

Early treatment of COVID-19 patients with convalescent plasma (CP) with high anti-SARS-CoV-2 IgG antibody levels is associated with a significantly reduced mortality [1] [2] [3] . The FDA established that units of CP with a signal-to-cut-off ratio of ≥12 in the Ortho VITROS SARS-CoV-2 IgG test could be qualified as high titre, but cut-off ratio has been recently lowered to ≥ 9.5 [4] . Finding donors with adequate titre of antibodies can be difficult, especially among younger donors with mild disease. We tried to explore whether the arrival of vaccines against COVID could help find optimal CP donors.

Sixteen CP donors were tested for anti-SARS-CoV-2 IgG after COVID-19 vaccination. Women comprised 68.8% of the patients, with a mean age of 41.1 years (SD: 10.46). Fourteen had received the Pfizer â vaccine (4 a single dose and 10 two doses) and two one dose of Moderna â vaccine. Importantly, most of them had previously been excluded as donors because of low antibody levels. Donor serum antibodies were assessed with the Ortho VITROS IgG assay (Ortho Clinical Diagnostics, NJ, USA), according to manufacturer's instructions. Signal-to-cutoff ratios for anti-SARS-CoV-2 IgG antibody levels were categorized as low (<9.5) or high (≥9.5).

The last measurement of antibody levels before the administration of the first dose of the vaccine was taken as a baseline determination (mean months: 3.3, SD: 1.98): 4 donors (25%) showed high levels and 12 (75%) showed low levels (median ratio: 3.0, IQR: 6.8). Post-vaccination anti-SARS-CoV-2 IgG antibody test was performed 7 to 29 days after the first dose (mean: 20.8, SD: 1.93). All donors presented high levels of antibodies (median ratio: 19.9, IQR: 1.9) significantly superior from their baseline antibody levels (Mann-Whitney test: z = -3.92, p-value: 0.000). There were no differences between donors who had received two doses or a single dose (median ratio: 20.1 vs. 19.3 respectively, p-value: 0.945). (Table 1 and Fig. 1) The use of CP can still play an important role in the treatment of patients suffering from COVID-19 infection, before vaccines become widely available or in immunosuppressed patients. FDA has recently clarified that the authorization for administration of CP under EUA is limited to high-titre plasma units [4] and that individuals who received a vaccine after diagnosis of COVID-19 are allowed as CP donors [5] . Our study shows that convalescent donors have a rapid and significant increase in anti-SARS-CoV-2 antibody levels within a few weeks of vaccination. Additional studies are needed to confirm antibody response with different kinds of vaccines, clinical efficacy Fig. 1 Evolution of SARS-CoV-2 IgG antibodies. Cut-off is set at 9.5 S/C. of this CP, and follow-up to discern whether long-term responses are achieved.

Treatment of Coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality

Convalescent plasma antibody levels and the risk of death from Covid-19

Early high-titer plasma therapy to prevent severe Covid-19 in older adults

Letter of Authorization, Reissuance of Convalescent Plasma EUA

FDA. Investigational COVID-19 Convalescent Plasma. Guidance for Industry. Food Drug Adm. 2021

The authors have not received any financial support or incentive to write the paper, either form public or private sources and state no conflict of interest whatsoever.